These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15298153)

  • 1. Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation.
    Blackall DP; Marques MB
    Am J Clin Pathol; 2004 Jun; 121 Suppl():S81-8. PubMed ID: 15298153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS).
    Scheiring J; Andreoli SP; Zimmerhackl LB
    Pediatr Nephrol; 2008 Oct; 23(10):1749-60. PubMed ID: 18704506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature.
    Ko H; Maymani H; Rojas-Hernandez C
    J Med Case Rep; 2016 Jun; 10():175. PubMed ID: 27301547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy for children with Shiga toxin-E. coli-associated hemolytic uremic syndrome].
    Ito K; Hattori M; Matsumoto N
    Nihon Rinsho; 2002 Jun; 60(6):1126-30. PubMed ID: 12078084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
    Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
    Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution and Interaction of Shiga Toxin Genes to
    Tarr GAM; Stokowski T; Shringi S; Tarr PI; Freedman SB; Oltean HN; Rabinowitz PM; Chui L
    Toxins (Basel); 2019 Oct; 11(10):. PubMed ID: 31635282
    [No Abstract]   [Full Text] [Related]  

  • 7. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
    J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.
    Zoja C; Buelli S; Morigi M
    Pediatr Nephrol; 2019 Mar; 34(3):379-388. PubMed ID: 29214442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).
    Khalid M; Andreoli S
    Pediatr Nephrol; 2019 Dec; 34(12):2495-2507. PubMed ID: 30382336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemolytic uremic syndrome: pathogenesis and update of interventions.
    Palermo MS; Exeni RA; Fernández GC
    Expert Rev Anti Infect Ther; 2009 Aug; 7(6):697-707. PubMed ID: 19681698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: distinct mechanisms of pathogenesis.
    Tarr PI
    Kidney Int Suppl; 2009 Feb; (112):S29-32. PubMed ID: 19180128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome.
    Braune SA; Wichmann D; von Heinz MC; Nierhaus A; Becker H; Meyer TN; Meyer GP; Müller-Schulz M; Fricke J; de Weerth A; Hoepker WW; Fiehler J; Magnus T; Gerloff C; Panzer U; Stahl RA; Wegscheider K; Kluge S
    Crit Care Med; 2013 Jul; 41(7):1702-10. PubMed ID: 23660733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases.
    Bianchi L; Gaiani F; Vincenzi F; Kayali S; Di Mario F; Leandro G; De' Angelis GL; Ruberto C
    Acta Biomed; 2018 Dec; 89(9-S):153-157. PubMed ID: 30561409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hemolytic uremic syndrome caused by enterohaemorrhagic Escherichia coli].
    Ibarra C; Goldstein J; Silberstein C; Zotta E; Belardo M; Repetto HA
    Arch Argent Pediatr; 2008 Oct; 106(5):435-42. PubMed ID: 19030644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemolytic uremic syndrome: an emerging health risk.
    Razzaq S
    Am Fam Physician; 2006 Sep; 74(6):991-6. PubMed ID: 17002034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.
    Zoja C; Buelli S; Morigi M
    Pediatr Nephrol; 2010 Nov; 25(11):2231-40. PubMed ID: 20424866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome.
    Ray PE; Liu XH
    Pediatr Nephrol; 2001 Oct; 16(10):823-39. PubMed ID: 11605791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enterohemorrhagic Escherichia coli and hemolytic-uremic syndrome in Argentina].
    Rivero MA; Padola NL; Etcheverría AI; Parma AE
    Medicina (B Aires); 2004; 64(4):352-6. PubMed ID: 15338982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse model for hemolytic uremic syndrome induced by outer membrane vesicles of Escherichia coli O157:H7.
    Kim SH; Lee YH; Lee SH; Lee SR; Huh JW; Kim SU; Chang KT
    FEMS Immunol Med Microbiol; 2011 Dec; 63(3):427-34. PubMed ID: 22029600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemolytic Uremic Syndrome.
    Cody EM; Dixon BP
    Pediatr Clin North Am; 2019 Feb; 66(1):235-246. PubMed ID: 30454746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.